|Day Low/High||79.45 / 80.47|
|52 Wk Low/High||69.30 / 106.67|
Eight PSAs chosen in first statewide contest to promote a tobacco-free generation
Ranked No. 1 in the Health Care: Pharmacy and Other Services sector
The country's largest pharmacy benefits manager is enjoying tailwinds after reporting a big jump in year-over-year profits.
Free screenings are one way CVS Health is supporting women's heart health and its commitment to the American Heart Association's Go Red For Women® movement
Once again, a number of our One-rated positions outperformed a rising overall market this week.
The FTC is considering antitrust issues, but the deal could go through.
President Trump made more promises.
The three major U.S. stock indexes post intraday record highs as oil prices rally and financial and energy shares rise.
Stocks rise as earnings drive the action Thursday, Twitter tanks as revenue misses estimates.
Stock futures trade higher Thursday but Twitter shares take it on the chin.
We have a president that seems likely to pursue a weaker dollar policy, and gold has surged.
U.S. stock futures are higher Thursday as investors remain concerned over policy uncertainty from the Trump administration.
Analysts are looking for more guidance on the company's pharmacy benefit management division.
The earnings parade continues on Thursday, Feb. 9.
CVS, Verizon and American Express are low volatility stocks to keep an eye on.
For the week of February 6, the markets await a host of earnings reports and economic data points.
Wall Street should expect the unexpected in week three of Trump's America.
Strong employment data and Trump call on job creation boost stability and power up the bulls for next week, says Jim Cramer.
It was a busy week of earnings for the portfolio as the market ended up largely unchanged.
Here are Thursday's top research calls, including downgrades for CVS, Edwards Lifesciences and Qorvo, and an upgrade for Tesoro.
Demographics will continue to favor health-care and pharmaceutical companies.
As border tax gets shaky, retailers show signs of life.
The portfolio had several outperformers during the first week of the new president's term and somewhat mixed earnings.
The comparison to the New York mob boss was only the beginning of Citron Research's inflammatory comments